Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Pancreatic Cancer Clinical Trial

— ViP  

Official title:

A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01601808
• Other study ID #: 2010-021951-26
• Secondary ID: 74555382
• Status: Recruiting
• Phase: Phase 2
• First received: February 22, 2012
• Last updated: May 16, 2012
• Start date: October 2011
• Est. completion date: October 2013

Study information

• Verified date: May 2012
• Source: University of Liverpool
• Contact: Zaira Yunus
• Phone: 0151 7948935
• Email: zyunus[@]liv.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: October 2013
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years.

• Histologically or cytologically proven pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas.

• Locally advanced or metastatic disease precluding curative surgical resection or definitive locally directed therapies such as chemo radiation. Patients who have relapsed following previously resected Pancreatic Cancer can be included.

• Contrast enhanced computerised tomography (CT) scan of the thorax, abdomen and pelvis within 28 days prior to commencing treatment.

• Unidimensionally measurable disease as shown by CT scan, in accordance with RECIST guidelines (version 1.1)

• ECOG performance status 0, 1 or 2 where the investigator feels that treatment with combination chemotherapy.

• Platelets =100 x 109/l; WBC = 3 x 109/l; neutrophils = 1.5 x 109/l at entry.

• Documented Life expectancy > 3 months.

• Informed written consent

Exclusion Criteria:

• Laboratory results:

• Serum bilirubin = 1.5x the upper limit of reference range (ULRR).

• Haemoglobin < 10G/dl

• Creatinine clearance < 30 mL/minute (calculated by Cockcroft-Gault formula)**. Patients with a creatinine clearance of =30mL/minute and <50mL/minute should begin vandetanib on a reduced dose of 200mg.

• Potassium, =4.0 mmol/L despite supplementation; or > 5.5 mmol/L

• Magnesium below the normal range despite supplementation, or > 1.23 mmol/L

• Serum calcium is > 2.9 mmol/L. In cases where serum calcium is below the normal range this can be substituted with the value for calcium adjusted for albumin, if this is below the normal range despite supplementation patients should be excluded.

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) >2.5 x ULRR or > 5x ULRR if judged by the investigator to be related to liver metastases.

• Medical or psychiatric conditions compromising informed consent.

• Intracerebral metastases or meningeal carcinomatosis.

• Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.

• Evidence of severe or uncontrolled systemic disease or any concurrent condition

• Clinically significant cardiovascular eventclassification of heart disease =2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.

• History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded.

• QTc prolongation with other medications that required discontinuation of that medication.

• Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.

• Presence of left bundle branch block (LBBB).

• QTc with Bazett's correction that is un-measurable or = 480 msec on screening ECG. Patients who are receiving a drug that has a risk of inducing Torsades-de-Pointes are excluded if QTc is = 460 msec.

• Any concurrent medication with a known risk of inducing Torsades-de-Pointes, that in the investigator's opinion cannot be discontinued, are allowed.

• Concomitant medications that are potent inducers.

• Hypertension not controlled by medical therapy.

• Currently active diarrhoea.

• Malabsorption syndrome.

• Pregnancy or breast feeding.

• Previous chemotherapy for locally advanced and metastatic disease. Adjuvant chemotherapy for resected pancreatic cancer will be permitted provided that chemotherapy was completed > 12 months previously.

• Radiotherapy within the last 4 weeks prior to start of study treatment.

• Concurrent malignancies or invasive cancers diagnosed within past 5 years.

• Chemotherapy directed at tumour apart from that described in this protocol.

• All men or women of reproductive potential, unless using at least two contraceptive precautions, one of which must be a condom.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Placebo
Orally once a day, continuously throughout the study
• Caprelsa (vandetanib)
Orally once a daily, continuously throughout the study.

Locations

Country	Name	City	State
United Kingdom	Belfast City Hospital	Belfast
United Kingdom	The Royal Bournemouth Hospital	Bournemouth
United Kingdom	Bristol Haematology and Oncology Centre	Bristol
United Kingdom	Royal Surrey County Hospital	Guildford
United Kingdom	Clatterbridge Centre for Oncology	Liverpool
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	Guys & St Thomas Hospital	London
United Kingdom	Royal Marsden Hospital	London
United Kingdom	St Bartholomew's Hospital	London
United Kingdom	The Christie Hospital	Manchester
United Kingdom	James Cook University Hospital	Middlesbrough
United Kingdom	Freeman Hospital	Newcastle
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Weston Park Hospital	Sheffield

Sponsors (2)

Lead Sponsor	Collaborator
University of Liverpool	AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	To assess whether survival times for patients receiving gemcitabine plus vandetanib are longer than for those patients receiving gemcitabine alone as first line treatment for advanced pancreatic cancer	Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	No
Secondary	Progression-free survival time		Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	No
Secondary	Objective response rate		Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	No
Secondary	Disease control rate		Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	No
Secondary	Number and types of adverse events		Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	Yes
Secondary	Patient pain assessment		Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation	No